Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment

Robert Marx, Yoh Sawatari, Michel Fortin, Vishtasb Broumand

Research output: Contribution to journalArticle

1118 Citations (Scopus)

Abstract

Purpose: Bisphosphonates inhibit bone resorption and thus bone renewal by suppressing the recruitment and activity of osteoclasts thus shortening their life span. Recently three bisphosphonates, Pamidronate (Aredia; Novartis Pharmaceuticals, East Haven, NJ), Zoledronate (Zometa; Novartis Pharmaceuticals), and Alendronate (Fosamax; Merck Co, West Point, VA) have been linked to painful refractory bone exposures in the jaws. Materials and Methods: One hundred-nineteen total cases of bisphosphonate-related bone exposure were reviewed. Results: Thirty-two of 119 patients (26%) received Aredia, 48 (40.3%) received Zometa, 36 (30.2%) received Aredia later changed to Zometa, and 3 (2.5%) received Fosamax. The mean induction time for clinical bone exposure and symptoms was 14.3 months for those who received Aredia, 12.1 months for those who received both, 9.4 months for those who received Zometa, and 3 years for those who received Fosamax. Sixty-two (52.1%) were treated for multiple myeloma, 50 (42%) for metastatic breast cancer, 4 (3.4%) for metastatic prostate cancer and 3 (2.5%) for osteoporosis. Presenting findings in addition to exposed bone were 37 (31.1%) asymptomatic, 82 (68.9%) with pain, 28 (23.5%) mobile teeth, and 21 (17.6%) with nonhealing fistulas. Eighty-one (68.1%) bone exposures occurred in the mandible alone, 33 (27.7%) in the maxilla, and 5 (4.2%) occurred in both jaws. Medical comorbidities included the malignancy itself 97.5%, previous and/or maintenance chemotherapy 97.5%, Dexamethasone 59.7%. Dental comorbidities included the presence of periodontitis 84%, dental caries 28.6%, abscessed teeth 13.4% root canal treatments 10.9%, and the presence of mandibular tori 9.2%. The precipitating event that produced the bone exposures were spontaneous 25.2%, tooth removals 37.8%, advanced periodontitis 28.6%, periodontal surgery 11.2%, dental implants 3.4% and root canal surgery 0.8%. Conclusions: Complete prevention of this complication in not currently possible. However, pre-therapy dental care reduces this incidence, and non-surgical dental procedures can prevent new cases. For those who present with painful exposed bone, effective control to a pain free state without resolution of the exposed bone is 90.1% effective using a regimen of antibiotics along with 0.12% chlorohexidine antiseptic mouth.

Original languageEnglish
Pages (from-to)1567-1575
Number of pages9
JournalJournal of Oral and Maxillofacial Surgery
Volume63
Issue number11
DOIs
StatePublished - Nov 1 2005

Fingerprint

Osteopetrosis
pamidronate
zoledronic acid
Osteonecrosis
Diphosphonates
Jaw
Bone and Bones
Alendronate
Tooth
Tooth Root
Therapeutics
Periodontitis
Dental Pulp Cavity
Comorbidity
Maintenance Chemotherapy
Personnel Selection
Local Anti-Infective Agents
Dental Implants
Dental Care
Maxilla

ASJC Scopus subject areas

  • Dentistry(all)
  • Surgery

Cite this

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws : Risk factors, recognition, prevention, and treatment. / Marx, Robert; Sawatari, Yoh; Fortin, Michel; Broumand, Vishtasb.

In: Journal of Oral and Maxillofacial Surgery, Vol. 63, No. 11, 01.11.2005, p. 1567-1575.

Research output: Contribution to journalArticle

@article{b241fae6713748cf862a79a7a20652f1,
title = "Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment",
abstract = "Purpose: Bisphosphonates inhibit bone resorption and thus bone renewal by suppressing the recruitment and activity of osteoclasts thus shortening their life span. Recently three bisphosphonates, Pamidronate (Aredia; Novartis Pharmaceuticals, East Haven, NJ), Zoledronate (Zometa; Novartis Pharmaceuticals), and Alendronate (Fosamax; Merck Co, West Point, VA) have been linked to painful refractory bone exposures in the jaws. Materials and Methods: One hundred-nineteen total cases of bisphosphonate-related bone exposure were reviewed. Results: Thirty-two of 119 patients (26{\%}) received Aredia, 48 (40.3{\%}) received Zometa, 36 (30.2{\%}) received Aredia later changed to Zometa, and 3 (2.5{\%}) received Fosamax. The mean induction time for clinical bone exposure and symptoms was 14.3 months for those who received Aredia, 12.1 months for those who received both, 9.4 months for those who received Zometa, and 3 years for those who received Fosamax. Sixty-two (52.1{\%}) were treated for multiple myeloma, 50 (42{\%}) for metastatic breast cancer, 4 (3.4{\%}) for metastatic prostate cancer and 3 (2.5{\%}) for osteoporosis. Presenting findings in addition to exposed bone were 37 (31.1{\%}) asymptomatic, 82 (68.9{\%}) with pain, 28 (23.5{\%}) mobile teeth, and 21 (17.6{\%}) with nonhealing fistulas. Eighty-one (68.1{\%}) bone exposures occurred in the mandible alone, 33 (27.7{\%}) in the maxilla, and 5 (4.2{\%}) occurred in both jaws. Medical comorbidities included the malignancy itself 97.5{\%}, previous and/or maintenance chemotherapy 97.5{\%}, Dexamethasone 59.7{\%}. Dental comorbidities included the presence of periodontitis 84{\%}, dental caries 28.6{\%}, abscessed teeth 13.4{\%} root canal treatments 10.9{\%}, and the presence of mandibular tori 9.2{\%}. The precipitating event that produced the bone exposures were spontaneous 25.2{\%}, tooth removals 37.8{\%}, advanced periodontitis 28.6{\%}, periodontal surgery 11.2{\%}, dental implants 3.4{\%} and root canal surgery 0.8{\%}. Conclusions: Complete prevention of this complication in not currently possible. However, pre-therapy dental care reduces this incidence, and non-surgical dental procedures can prevent new cases. For those who present with painful exposed bone, effective control to a pain free state without resolution of the exposed bone is 90.1{\%} effective using a regimen of antibiotics along with 0.12{\%} chlorohexidine antiseptic mouth.",
author = "Robert Marx and Yoh Sawatari and Michel Fortin and Vishtasb Broumand",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.joms.2005.07.010",
language = "English",
volume = "63",
pages = "1567--1575",
journal = "Journal of Oral and Maxillofacial Surgery",
issn = "0278-2391",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws

T2 - Risk factors, recognition, prevention, and treatment

AU - Marx, Robert

AU - Sawatari, Yoh

AU - Fortin, Michel

AU - Broumand, Vishtasb

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Purpose: Bisphosphonates inhibit bone resorption and thus bone renewal by suppressing the recruitment and activity of osteoclasts thus shortening their life span. Recently three bisphosphonates, Pamidronate (Aredia; Novartis Pharmaceuticals, East Haven, NJ), Zoledronate (Zometa; Novartis Pharmaceuticals), and Alendronate (Fosamax; Merck Co, West Point, VA) have been linked to painful refractory bone exposures in the jaws. Materials and Methods: One hundred-nineteen total cases of bisphosphonate-related bone exposure were reviewed. Results: Thirty-two of 119 patients (26%) received Aredia, 48 (40.3%) received Zometa, 36 (30.2%) received Aredia later changed to Zometa, and 3 (2.5%) received Fosamax. The mean induction time for clinical bone exposure and symptoms was 14.3 months for those who received Aredia, 12.1 months for those who received both, 9.4 months for those who received Zometa, and 3 years for those who received Fosamax. Sixty-two (52.1%) were treated for multiple myeloma, 50 (42%) for metastatic breast cancer, 4 (3.4%) for metastatic prostate cancer and 3 (2.5%) for osteoporosis. Presenting findings in addition to exposed bone were 37 (31.1%) asymptomatic, 82 (68.9%) with pain, 28 (23.5%) mobile teeth, and 21 (17.6%) with nonhealing fistulas. Eighty-one (68.1%) bone exposures occurred in the mandible alone, 33 (27.7%) in the maxilla, and 5 (4.2%) occurred in both jaws. Medical comorbidities included the malignancy itself 97.5%, previous and/or maintenance chemotherapy 97.5%, Dexamethasone 59.7%. Dental comorbidities included the presence of periodontitis 84%, dental caries 28.6%, abscessed teeth 13.4% root canal treatments 10.9%, and the presence of mandibular tori 9.2%. The precipitating event that produced the bone exposures were spontaneous 25.2%, tooth removals 37.8%, advanced periodontitis 28.6%, periodontal surgery 11.2%, dental implants 3.4% and root canal surgery 0.8%. Conclusions: Complete prevention of this complication in not currently possible. However, pre-therapy dental care reduces this incidence, and non-surgical dental procedures can prevent new cases. For those who present with painful exposed bone, effective control to a pain free state without resolution of the exposed bone is 90.1% effective using a regimen of antibiotics along with 0.12% chlorohexidine antiseptic mouth.

AB - Purpose: Bisphosphonates inhibit bone resorption and thus bone renewal by suppressing the recruitment and activity of osteoclasts thus shortening their life span. Recently three bisphosphonates, Pamidronate (Aredia; Novartis Pharmaceuticals, East Haven, NJ), Zoledronate (Zometa; Novartis Pharmaceuticals), and Alendronate (Fosamax; Merck Co, West Point, VA) have been linked to painful refractory bone exposures in the jaws. Materials and Methods: One hundred-nineteen total cases of bisphosphonate-related bone exposure were reviewed. Results: Thirty-two of 119 patients (26%) received Aredia, 48 (40.3%) received Zometa, 36 (30.2%) received Aredia later changed to Zometa, and 3 (2.5%) received Fosamax. The mean induction time for clinical bone exposure and symptoms was 14.3 months for those who received Aredia, 12.1 months for those who received both, 9.4 months for those who received Zometa, and 3 years for those who received Fosamax. Sixty-two (52.1%) were treated for multiple myeloma, 50 (42%) for metastatic breast cancer, 4 (3.4%) for metastatic prostate cancer and 3 (2.5%) for osteoporosis. Presenting findings in addition to exposed bone were 37 (31.1%) asymptomatic, 82 (68.9%) with pain, 28 (23.5%) mobile teeth, and 21 (17.6%) with nonhealing fistulas. Eighty-one (68.1%) bone exposures occurred in the mandible alone, 33 (27.7%) in the maxilla, and 5 (4.2%) occurred in both jaws. Medical comorbidities included the malignancy itself 97.5%, previous and/or maintenance chemotherapy 97.5%, Dexamethasone 59.7%. Dental comorbidities included the presence of periodontitis 84%, dental caries 28.6%, abscessed teeth 13.4% root canal treatments 10.9%, and the presence of mandibular tori 9.2%. The precipitating event that produced the bone exposures were spontaneous 25.2%, tooth removals 37.8%, advanced periodontitis 28.6%, periodontal surgery 11.2%, dental implants 3.4% and root canal surgery 0.8%. Conclusions: Complete prevention of this complication in not currently possible. However, pre-therapy dental care reduces this incidence, and non-surgical dental procedures can prevent new cases. For those who present with painful exposed bone, effective control to a pain free state without resolution of the exposed bone is 90.1% effective using a regimen of antibiotics along with 0.12% chlorohexidine antiseptic mouth.

UR - http://www.scopus.com/inward/record.url?scp=27344453813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27344453813&partnerID=8YFLogxK

U2 - 10.1016/j.joms.2005.07.010

DO - 10.1016/j.joms.2005.07.010

M3 - Article

C2 - 16243172

AN - SCOPUS:27344453813

VL - 63

SP - 1567

EP - 1575

JO - Journal of Oral and Maxillofacial Surgery

JF - Journal of Oral and Maxillofacial Surgery

SN - 0278-2391

IS - 11

ER -